kynuramine has been researched along with Cancer of Pancreas in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bonior, J; Góralska, M; Jastrzębska, M; Jaworek, J; Leja-Szpak, A; Link-Lenczowski, P; Nawrot-Porąbka, K; Pierzchalski, P | 2 |
2 other study(ies) available for kynuramine and Cancer of Pancreas
| Article | Year |
|---|---|
Melatonin and its metabolite N1-acetyl-N2-formyl-5-methoxykynuramine (afmk) enhance chemosensitivity to gemcitabine in pancreatic carcinoma cells (PANC-1).
Topics: Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Cell Survival; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Gemcitabine; Humans; Kynuramine; Melatonin; Pancreatic Neoplasms | 2018 |
Kynuramines induce overexpression of heat shock proteins in pancreatic cancer cells via 5-hydroxytryptamine and MT1/MT2 receptors.
Topics: Cell Line, Tumor; Heat-Shock Proteins; Humans; Ketanserin; Kynuramine; Melatonin; Pancreatic Neoplasms; Receptor, Melatonin, MT1; Receptor, Melatonin, MT2; Serotonin; Tropanes; Tryptamines; Tryptophan | 2015 |